Evidence map›Paper›PMID 34638427›Full record

ReviewCancers2021

Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide

Roberto Campagna, Valentina Pozzi, Davide Sartini, Eleonora Salvolini, Valerio Brisigotti, Elisa Molinelli, Anna Campanati, Annamaria Offidani, Monica Emanuelli

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Inhibitors of NADInternational journal of molecular sciences · 2024
    Review
  11. Article
  12. Role of SLC7A11/xCT in Ovarian Cancer.International journal of molecular sciences · 2024
    Review
  13. Review
  14. Review
  15. Review
  16. Update on the Molecular Pathology of Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2023
    Review
  17. NADAntioxidants (Basel, Switzerland) · 2023
    Review
  18. Review
  19. Review: The Key Factors to Melanomagenesis.Life (Basel, Switzerland) · 2023
    Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Roberto CampagnaDepartment of Clinical Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.ORCID 0000-0003-2607-2734
Valentina PozziDepartment of Clinical Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Davide SartiniDepartment of Clinical Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Eleonora SalvoliniDepartment of Clinical Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.ORCID 0000-0003-2405-8947
Valerio BrisigottiDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.ORCID 0000-0002-3033-8024
Elisa MolinelliDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Anna CampanatiDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Annamaria OffidaniDepartment of Clinical and Molecular Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Monica EmanuelliDepartment of Clinical Sciences, Polytechnic University of Marche, 60100 Ancona, Italy.
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin cancers (SC) collectively represent the most common type of malignancy in white populations. SC includes two main forms: malignant melanoma and non-melanoma skin cancer (NMSC). NMSC includes different subtypes, namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC), and keratoacanthoma (KA), together with the two pre-neoplastic conditions Bowen disease (BD) and actinic keratosis (AK). Both malignant melanoma and NMSC are showing an increasing incidence rate worldwide, thus representing an important challenge for health care systems, also because, with some exceptions, SC are generally characterized by an aggressive behavior and are often diagnosed late. Thus, identifying new biomarkers suitable for diagnosis, as well as for prognosis and targeted therapy is mandatory. Nicotinamide

Indexed as

biomarkermelanomanicotinamide N-methyltransferasenon-melanoma skin cancerskin cancer

Identifiers

PMID34638427
PMCPMC8508019
OpenAlexW3202380981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.